Novan Inc

+0.16 (+3.35%)
Other Pre-Announcement

Novan Inc Reported Qtrly Loss Per Share $0.34

Published: 11/10/2021 12:39 GMT
Novan Inc (NOVN) - Novan Inc - Sees Sb019 Ind Submission to Initiate Phase 1 Study in Healthy Volunteers Targeted for No Later Than Q2 2022.
Novan Inc - Qtrly Loss per Share $0.34.
Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results.
Novan Inc - Believes Existing Cash and Cash Equivalents Balance As of Sept 30, Will Provide Adequate Liquidity to Fund Operating Needs Into Q4 of 2022.
Novan Inc - Sees Sb019 Phase 2/3 Study(ies) Targeted for 2023, Subject to Obtaining Additional Financing Or Strategic Partnering.
Novan Inc - Sees Potential Submission of an Sb019 NDA in 2024.
Novan - Executing on Plans for 3 Potential NDA Filings in 3 Years With First Submission in Q3 2022 for Lead Program Sb206 in Molluscum Contagiosum.
Further Company Coverage: Novno (reporting by Nandhini Srinivasan).